statements

The stock has been placed in Additional Surveillance Measure (ASM) list LTASM - I.

Choksi Laboratories Ltd.

BSE: 526546

Sector: Healthcare

Industry Group: Healthcare Services

Industry: Healthcare Service Provider

137.00+5.9 (+4.50%)

21 Aug, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Choksi Laboratories Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS	12M IR
Total Revenue	31.20	33.75	28.16	25.69	30.04	34.44	36.70	41.78	46.01	46.83
Cost of Operating Revenue	6.64	7.62	7.81	8.11	8.26	7.71	8.27	9.60	14.92	16.14
Gross Profit	24.56	26.12	20.35	17.58	21.78	26.73	28.42	32.19	31.08	30.68
Gross Margin	78.7	77.4	72.3	68.4	72.5	77.6	77.5	77.0	67.6	65.5
Total Operating Expenses	28.03	30.16	29.18	26.17	26.58	29.70	32.19	37.05	40.96	41.72
Operating Profit	3.17	3.59	-1.02	-0.48	3.46	4.74	4.51	4.74	5.04	5.11
Operating Margin	10.2	10.6	-3.6	-1.9	11.5	13.8	12.3	11.3	11.0	10.9
Financing Income/(Expense) - Net	-1.60	-1.53	-1.89	-2.82	-3.21	-3.49	-3.01	-2.65	-2.82	-2.95
Profit before Taxes	1.93	2.29	-5.71	-2.81	0.37	3.72	1.66	2.15	3.19	3.17
Income Taxes	0.59	0.69	-1.83	-0.20	0.16	0.51	0.55	0.63	1.23	1.00
Profit after Tax	1.35	1.60	-3.88	-2.61	0.21	3.21	1.11	1.52	1.96	2.16
PAT Margin	4.3	4.7	-13.8	-10.2	0.7	9.3	3.0	3.6	4.3	4.6
EPS - Basic - ex Extraordinary Items	1.93	2.30	-5.58	-3.74	0.30	4.61	1.59	2.19	2.82	3.11
EPS - Diluted - ex Extraordinary Items	1.93	2.30	-5.58	-3.74	0.30	4.61	1.59	2.19	2.82	3.11
EBIT	3.17	3.59	-1.02	-0.48	3.46	4.74	4.51	4.74	5.04	5.11
EBITDA	6.33	7.26	3.54	4.12	8.89	10.24	10.22	11.23	12.13	12.49
EBITDA Margin	20.3	21.5	12.6	16.1	29.6	29.7	27.9	26.9	26.4	26.7

Balance Sheet

Abridged

Understanding Balance Sheet

Choksi Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	15.02	16.30	16.54	13.03	14.06	13.95	14.57	16.32	18.87
Long-Term Investments	3.50	0.48	0.54	0.67	0.70	0.32	0.53	0.84	0.85
Property Plant & Equipment - Net	25.43	37.74	46.00	50.54	47.91	44.75	46.07	47.13	51.54
Total Non-Current Assets	29.66	39.04	48.46	53.35	50.41	46.42	47.38	49.01	53.05
Total Assets	44.68	55.35	65.01	66.38	64.47	60.36	61.95	65.33	71.92
Total Current Liabilities	15.60	13.48	14.48	16.22	15.57	12.51	18.85	23.88	23.09
Long Term Debt	5.52	14.00	27.36	31.35	29.60	25.21	19.08	15.96	21.16
Total Non-Current Liabilities	6.68	17.86	30.31	32.41	30.99	26.74	20.89	17.85	23.26
Total Liabilities	22.28	31.34	44.79	48.63	46.56	39.26	39.74	41.73	46.35
Total Shareholders' Equity	22.40	24.01	20.22	17.75	17.90	21.11	22.21	23.60	25.58
Total Equity	22.40	24.01	20.22	17.75	17.90	21.11	22.21	23.60	25.58
Total Liabilities & Equity	44.68	55.35	65.01	66.38	64.47	60.36	61.95	65.33	71.92

Cash Flow

Abridged

Understanding Cash Flow Statement

Choksi Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2018 Mar 31	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	3.35	2.91	-1.30	4.90	6.96	8.07	7.11	7.00	9.59
Working Capital - Increase/(Decrease)	1.66	2.68	2.57	-1.34	-2.18	-3.11	1.60	2.19	-4.37
Net CF from Operating Activities	5.02	5.60	1.26	3.56	4.78	4.96	8.71	9.19	5.22
Capital Expenditures - Net	4.95	10.00	13.99	8.09	2.83	0.91	7.00	7.68	7.25
Net CF from Investing Activities	-5.27	-10.00	-14.05	-8.09	-2.82	-0.91	-6.81	-7.66	-7.25
Debt - LT & ST - Issuance/(Retirement) - Total	0.65	3.67	12.98	4.40	-1.86	-4.87	-1.58	-1.57	1.62
Net Cash Flow from Financing Activities	0.65	3.67	12.98	4.40	-1.86	-4.12	-1.58	-1.57	1.62
Free Cash Flow to Equity	0.72	-0.73	0.25	-0.12	0.10	-0.82	0.13	-0.06	-0.41
Free Operating CF net dividend	0.07	-4.40	-12.73	-4.53	1.92	0.81	1.62	1.50	-2.95
Free Operating CF	0.07	-4.40	-12.73	-4.53	1.92	0.81	1.62	1.50	-2.95

Business Segment Analysis

Choksi Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

We don't have enough data to show business segment analysis for Choksi Laboratories Ltd.

Regional Segment Analysis

Choksi Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Choksi Laboratories Ltd.

Historical Segment Analysis

Track how Choksi Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

We don't have enough data to show segments for Choksi Laboratories Ltd.

Frequently Asked Questions

What is the revenue of Choksi Laboratories Ltd.?

The latest trailing twelve month revenue of Choksi Laboratories Ltd. is ₹ 46.83 Cr, reflecting a 1-year growth of 10.73% and a 3-year CAGR of 10.15%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Choksi Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Choksi Laboratories Ltd. is ₹ 2.16 Cr, with a 3-year earnings CAGR of -13.11%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Choksi Laboratories Ltd.?

The trailing twelve month EBITDA of Choksi Laboratories Ltd. is approximately ₹ 5.11 Cr (based on an operating margin of 10.91%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Choksi Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Choksi Laboratories Ltd. is 3.11. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Choksi Laboratories Ltd.?

The debt-to-equity ratio of Choksi Laboratories Ltd. stands at 1.34. The interest coverage ratio is 1.73x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Choksi Laboratories Ltd.?

The estimated book value per share of Choksi Laboratories Ltd. is 36.72 (derived from a P/B ratio of 3.73 and market price of ₹ 137.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Choksi Laboratories Ltd.?

The trailing twelve month operating cash flow of Choksi Laboratories Ltd. is ₹ 5.22 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Choksi Laboratories Ltd. report consolidated or standalone financials?

Choksi Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.